Evidence map›Paper›PMID 26552971›Full record

Trial reportAntimicrobial agents and chemotherapy2016

In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study.

Eliana S Armstrong, David J Farrell, Melissa Palchak, Judith N Steenbergen

Abstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Spotlight on New Antibiotics for the Treatment of Pneumonia.Clinical medicine insights. Circulatory, respiratory and pulmonary medicine · 2020
    Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eliana S ArmstrongMerck & Co., Inc., Kenilworth, New Jersey, USA eliana.armstrong@merck.com.
David J FarrellJMI Laboratories, North Liberty, Iowa, USA.
Melissa PalchakMerck & Co., Inc., Kenilworth, New Jersey, USA.
Judith N SteenbergenMerck & Co., Inc., Kenilworth, New Jersey, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The in vitro activities of ceftolozane-tazobactam, meropenem, and metronidazole were determined against anaerobic organisms isolated from patients with complicated intraabdominal infections (cIAI) in global phase III studies. Ceftolozane-tazobactam activity was highly variable among different species of the Bacteroides fragilis group, with MIC90 values ranging from 2 to 64 μg/ml. More-potent in vitro activity was observed against selected Gram-positive anaerobic organisms; however, small numbers of isolates were available, and, therefore, the clinical significance of these results is unknown. Variable activity of ceftolozane-tazobactam against anaerobic organisms necessitates use in combination with metronidazole for the treatment of cIAI.

Indexed as

AnaerobiosisAnti-Bacterial AgentsBacteroidesBacteroides fragilisBacteroides InfectionsCephalosporinsDrug Therapy, CombinationGram-Positive BacteriaGram-Positive Bacterial InfectionsHumansIntraabdominal InfectionsMetronidazoleMicrobial Sensitivity TestsPenicillanic AcidTazobactamAnti-Bacterial Agentsceftolozane, tazobactam drug combinationCephalosporinsMetronidazolePenicillanic AcidTazobactam

Identifiers

PMID26552971
PMCPMC4704157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.